Black checkmark with a sparkle and a curved line underneath on a white background.
Company

MAXCYTE, INC.

Ticker
MXCT
Sector
Industry
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include a decline in Q3 loss, launch of new off-target assays for base editing therapies, a multi-platform technology license partnership with Genentech, and the acquisition of Akron Bioproducts.

Recent developments:
  • MaxCyte reported a decline in Q3 loss, reflecting operational progress [N1].
  • The company launched new off-target assays for base editing therapies, expanding its assay technology offerings [N5].
  • MaxCyte signed a multi-platform technology license partnership with Genentech, enhancing collaboration opportunities [N4].
  • MaxCyte announced the acquisition of Akron Bioproducts, expanding its capabilities and market presence [N1].
Overview

MaxCyte, Inc. operates as a commercial cell engineering company focused on enabling technologies for next-generation cell therapeutics, including cell and gene therapies. Its proprietary Flow Electroporation® technology facilitates the delivery of molecules into a wide variety of cells with high efficiency and viability. The company’s ExPERT platform comprises five instruments and associated disposables and consumables designed to support cell engineering from discovery through clinical development to commercial manufacturing. MaxCyte’s customer base includes leading biopharmaceutical companies, biotechnology firms, and academic institutions. The company’s business model generates revenue from instrument sales, disposables, licensing fees, and milestone and sales-based payments under strategic partnership licenses (SPLs). MaxCyte has a robust intellectual property portfolio and a strong focus on non-viral delivery methods to address the growing complexity of cell therapies. The company reported Q3 2026 revenue of $10.15 million and a net loss of $4.76 million, with strong liquidity as of September 30, 2026.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. MaxCyte, Inc. is a cell engineering company specializing in proprietary Flow Electroporation technology used in cell and gene therapy development. The company’s ExPERT platform supports scalable cell engineering from research to commercial manufacturing. MaxCyte’s business model includes instrument sales, consumables, licensing fees, and milestone payments under strategic partnerships. As of Q3 2026, the company reported $10.15 million in revenue and a net loss of $4.76 million, with strong liquidity ratios. Recent news highlights include a decline in Q3 loss, new assay launches, a partnership with Genentech, and acquisition of Akron Bioproducts.

Scenarios for MXCT

Bull case model:

MaxCyte’s technology platform addresses the growing demand for non-viral delivery methods in the expanding cell and gene therapy market. The company’s ExPERT platform supports complex cellular engineering at scale, enabling customers to develop next-generation cell therapies with improved efficacy and manufacturing efficiency. The acquisition of SeQure Dx expands assay capabilities for gene editing assessment, enhancing service offerings. Strategic partnerships, including a recent license agreement with Genentech and acquisition of Akron Bioproducts, may broaden market reach and technology applications. The recurring revenue model from instrument licenses and consumables, combined with milestone opportunities from SPL agreements, provides multiple revenue streams. Strong liquidity supports ongoing R&D and operational activities.

Bear case model:

MaxCyte operates in a highly competitive and rapidly evolving cell therapy technology market, where technological advances and customer preferences may shift. The company reported net losses as of Q3 2026, indicating ongoing investment and operational costs exceeding revenues. Dependence on milestone payments from SPL agreements introduces variability and uncertainty in revenue realization. The complexity of regulatory environments and the need for continued innovation pose execution risks. Market adoption of non-viral delivery methods, while growing, may face challenges from alternative technologies. Integration of acquisitions and partnerships requires effective management to realize anticipated benefits.

Moat:

MaxCyte’s competitive strengths include its proprietary and patented Flow Electroporation technology platform, which has been developed and optimized over more than 25 years. The ExPERT platform offers high delivery efficiency, viability, flexibility, and scalability from research to cGMP manufacturing on a single platform. The company’s extensive intellectual property portfolio with over 200 granted patents and more than 100 pending applications supports its technology leadership. Its strategic SPL agreements provide recurring revenue streams and potential milestone payments tied to customer program success, reducing clinical risk and development timelines. The company’s FDA Master File supports regulatory submissions for customers, enhancing adoption. Additionally, MaxCyte’s experienced management and scientific teams with deep domain expertise contribute to its competitive advantage.

Risks overview
Risks summary
MaxCyte faces risks related to technology adoption in a competitive market, financial performance variability due to milestone-based revenues, regulatory uncertainties, and integration of acquisitions.
Risks details:

• Technology Adoption Risk: The cell therapy market is evolving with competing technologies; failure to maintain technological leadership or customer adoption could impact business performance.
• Financial Performance Risk: The company reported net losses and relies on milestone payments, which may be variable and uncertain, affecting financial stability.
• Regulatory Risk: Changes in regulatory requirements or delays in customer product approvals could affect demand for MaxCyte’s platform and services.
• Integration Risk: Acquisitions such as SeQure Dx and Akron Bioproducts require successful integration to realize strategic benefits.

FINAL FORECAST FOR MXCT

Final take one line
MaxCyte, Inc. demonstrates very high visibility through detailed SEC disclosures and recent news on technology advancements, partnerships, and financial results.
Final take 12 to 24 month view

Business trends: Increasing adoption of non-viral delivery technologies in cell and gene therapy, expansion of assay services, and strategic partnerships.
Execution milestones: Integration of acquisitions like SeQure Dx and Akron Bioproducts, expansion of SPL agreements, and product launches such as new off-target assays.
Key risks: Competitive technology landscape, variability in milestone-based revenues, regulatory uncertainties, and integration challenges.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • MaxCyte, Inc. is a commercial cell engineering company focused on enabling platform technologies for next-generation cell therapeutics including cell and gene therapies and cell-based research and development [S1].
  • The company has developed and commercialized proprietary Flow Electroporation® technology used by biopharmaceutical companies for engineering a wide variety of cells [S1].
  • Electroporation is a method to introduce molecules into cells by applying an electric field to increase cell membrane permeability temporarily [S1].
  • MaxCyte's ExPERT platform, based on Flow Electroporation technology, addresses the cell therapy market from discovery through commercialization and includes five instruments (DTx, ATx, STx, GTx, VLx) plus proprietary disposables and consumables [S1].
  • The company acquired SeQure Dx in January 2025, expanding its assay technologies for on-target and off-target gene editing assessment services [S1].
  • MaxCyte's customer base includes leading biopharmaceutical companies, biotechnology firms, and academic institutions, with 32 SPL customers and a majority of the top 25 pharmaceutical companies by 2024 revenue [S1].
  • The Flow Electroporation technology is used by one SPL customer to engineer the first FDA-approved ex-vivo cell therapy as of December 2023 [S1].
  • The company’s business model includes sales of instruments, disposables, consumables, annual instrument license fees, and potential milestone and sales-based payments under SPL agreements [S1].
  • MaxCyte has over 31 SPL agreements with a total pre-commercial milestone opportunity exceeding $2 billion, including $130 million from 13 active clinical programs as of December 31, 2025 [S1].
  • The company reported Q3 2026 revenue of $10.15 million and a net loss of $4.76 million, with EPS of -$0.05 per share as of September 30, 2026 [S2].
  • Liquidity ratios as of September 30, 2026, include a current ratio of 7.83 and a cash ratio of 6.36, with cash and equivalents of $13.37 million and short-term investments of $87.91 million [S2].
  • Recent developments include a decline in Q3 loss, launch of new off-target assays for base editing therapies, and a multi-platform technology license partnership with Genentech [N1][N4][N5].
  • MaxCyte announced the acquisition of Akron Bioproducts in November 2026 [N1].
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-25 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | MaxCyte, Inc. Q3 Loss Declines | https://www.nasdaq.com/articles/maxcyte-inc-q3-loss-declines
  • N2 | 2026-11-05 | www.nasdaq.com | Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/keros-therapeutics-inc-kros-q3-earnings-and-revenues-surpass-estimates
  • N3 | 2026-10-29 | www.nasdaq.com | Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass Estimates | https://www.nasdaq.com/articles/fortrea-holdings-inc-ftre-q3-earnings-and-revenues-surpass-estimates
  • N4 | 2026-08-19 | www.nasdaq.com | MaxCyte (MXCT) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/maxcyte-mxct-q2-2026-earnings-call-transcript
  • N5 | 2026-08-19 | www.nasdaq.com | MaxCyte Launches New Off-Target Assays For Base Editing Therapies | https://www.nasdaq.com/articles/maxcyte-launches-new-target-assays-base-editing-therapies
  • N6 | 2026-08-13 | www.nasdaq.com | MaxCyte Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/maxcyte-q2-earnings-call-highlights
  • N7 | 2026-08-12 | www.nasdaq.com | MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/maxcyte-inc-mxct-reports-q2-loss-beats-revenue-estimates
  • N8 | 2026-08-11 | www.nasdaq.com | Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/adherex-technologies-inc-fenc-beats-q2-earnings-and-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine